{"id":3604,"date":"2026-06-04T08:18:48","date_gmt":"2026-06-04T15:18:48","guid":{"rendered":"https:\/\/xpharma.com.cn\/?p=3604"},"modified":"2026-06-04T08:47:04","modified_gmt":"2026-06-04T15:47:04","slug":"bristol-myers-squibb-co%ef%bc%9amezigdomide-formally-included-in-the-priority-review-and-approval-procedure","status":"publish","type":"post","link":"https:\/\/xpharma.com.cn\/index.php\/news\/bristol-myers-squibb-co%ef%bc%9amezigdomide-formally-included-in-the-priority-review-and-approval-procedure\/","title":{"rendered":"Bristol-Myers Squibb Co\uff1aMezigdomide\u00a0formally included in the priority review and approval procedure."},"content":{"rendered":"\n<figure class=\"wp-block-image size-full is-resized\"><img fetchpriority=\"high\" decoding=\"async\" width=\"640\" height=\"470\" src=\"https:\/\/xpharma.com.cn\/wp-content\/uploads\/2026\/06\/CgoaEGY7RqmEcEocAAAAAIHLW7c093.png\" alt=\"\" class=\"wp-image-3607\" style=\"object-fit:cover;width:420px;height:310px\" srcset=\"https:\/\/xpharma.com.cn\/wp-content\/uploads\/2026\/06\/CgoaEGY7RqmEcEocAAAAAIHLW7c093.png 640w, https:\/\/xpharma.com.cn\/wp-content\/uploads\/2026\/06\/CgoaEGY7RqmEcEocAAAAAIHLW7c093-300x220.png 300w, https:\/\/xpharma.com.cn\/wp-content\/uploads\/2026\/06\/CgoaEGY7RqmEcEocAAAAAIHLW7c093-500x367.png 500w\" sizes=\"(max-width: 640px) 100vw, 640px\" \/><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">On June 2, the official website of the CDE announced that Bristol Myers Squibb&#8217;s (BMS) Mezigdomide capsules have been formally included in the priority review and approval procedure, which is expected to accelerate its approval for marketing in China. The drug is primarily indicated for the treatment of adult patients with relapsed\/refractory multiple myeloma, offering a next-generation therapeutic option for clinical practice.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">At the 2026 ASCO Annual Meeting, BMS announced the initial positive results from the pivotal Phase III SUCCESSOR-2 (NCT05552976) study of Mezigdomide. This head-to-head study compared the efficacy and safety of the MeziKd regimen (Mezigdomide + Carfilzomib + Dexamethasone) versus the classic Kd regimen (Carfilzomib + Dexamethasone) in patients with relapsed\/refractory multiple myeloma.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Based on the core clinical data, the combination regimen demonstrated clear advantages: the median progression-free survival (PFS) in the MeziKd group reached 18.0 months, significantly higher than 8.3 months in the control group; the overall response rate (ORR) was 80.2%, compared with 53.4% in the control group; and the rate of complete response or better (\u2265CR) was 26.7%, far exceeding the 8.9% in the control group, representing a marked improvement in overall efficacy.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">In addition to Mezigdomide, BMS is simultaneously advancing another next-generation oral myeloma drug, Iberdomide, for which a marketing application has already been submitted to the FDA, with a target PDUFA action date of August 17, 2026. Both novel drugs belong to the class of CELMoDs (CRBN E3 Ligase Modulators), which are molecular glue drugs. Their core mechanism of action involves mediating the entry of pathogenic proteins into the cellular degradation system, thereby exerting therapeutic effects.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Buy Mezigdomide\u00a0online from China and save up to 80% on costs . no insurance needed . compare prices from a certified HongKong pharmacy .with fast shipping. Contact us now on WhatsApp to get the latest prices.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n","protected":false},"excerpt":{"rendered":"<p>On June 2, the official website of the CDE announced that Bristol Myers Squibb&#8217;s (BMS) Mezigdomide capsules have been formally included in the priority review and approval procedure, which is expected to accelerate its approval for marketing in China. The drug is primarily indicated for the treatment of adult patients with relapsed\/refractory multiple myeloma, offering [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[16],"tags":[],"class_list":["post-3604","post","type-post","status-publish","format-standard","hentry","category-news"],"blocksy_meta":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Bristol-Myers Squibb Co\uff1aMezigdomide\u00a0formally included in the priority review and approval procedure. - Xpharma China<\/title>\n<meta name=\"description\" content=\"Bristol-Myers Squibb Co\uff1aMezigdomide\u00a0formally included in the priority review and approval procedure. - Xpharma China\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/xpharma.com.cn\/index.php\/news\/bristol-myers-squibb-co\uff1amezigdomide-formally-included-in-the-priority-review-and-approval-procedure\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Bristol-Myers Squibb Co\uff1aMezigdomide\u00a0formally included in the priority review and approval procedure. - Xpharma China\" \/>\n<meta property=\"og:description\" content=\"Bristol-Myers Squibb Co\uff1aMezigdomide\u00a0formally included in the priority review and approval procedure. - Xpharma China\" \/>\n<meta property=\"og:url\" content=\"https:\/\/xpharma.com.cn\/index.php\/news\/bristol-myers-squibb-co\uff1amezigdomide-formally-included-in-the-priority-review-and-approval-procedure\/\" \/>\n<meta property=\"og:site_name\" content=\"Xpharma China\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/61590027634719\/\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-04T15:18:48+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-04T15:47:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/xpharma.com.cn\/wp-content\/uploads\/2026\/06\/CgoaEGY7RqmEcEocAAAAAIHLW7c093.png\" \/>\n\t<meta property=\"og:image:width\" content=\"640\" \/>\n\t<meta property=\"og:image:height\" content=\"470\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"xpharmanews\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@Xpharma007\" \/>\n<meta name=\"twitter:site\" content=\"@Xpharma007\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"xpharmanews\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"NewsArticle\",\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/news\\\/bristol-myers-squibb-co%ef%bc%9amezigdomide-formally-included-in-the-priority-review-and-approval-procedure\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/news\\\/bristol-myers-squibb-co%ef%bc%9amezigdomide-formally-included-in-the-priority-review-and-approval-procedure\\\/\"},\"author\":{\"name\":\"xpharmanews\",\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/#\\\/schema\\\/person\\\/c292b26c0a3311036ce0f5ab28a1ea05\"},\"headline\":\"Bristol-Myers Squibb Co\uff1aMezigdomide\u00a0formally included in the priority review and approval procedure.\",\"datePublished\":\"2026-06-04T15:18:48+00:00\",\"dateModified\":\"2026-06-04T15:47:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/news\\\/bristol-myers-squibb-co%ef%bc%9amezigdomide-formally-included-in-the-priority-review-and-approval-procedure\\\/\"},\"wordCount\":299,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/news\\\/bristol-myers-squibb-co%ef%bc%9amezigdomide-formally-included-in-the-priority-review-and-approval-procedure\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/xpharma.com.cn\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/CgoaEGY7RqmEcEocAAAAAIHLW7c093.png\",\"articleSection\":[\"Approved News\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/news\\\/bristol-myers-squibb-co%ef%bc%9amezigdomide-formally-included-in-the-priority-review-and-approval-procedure\\\/#respond\"]}]},{\"@type\":[\"WebPage\",\"MedicalWebPage\"],\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/news\\\/bristol-myers-squibb-co%ef%bc%9amezigdomide-formally-included-in-the-priority-review-and-approval-procedure\\\/\",\"url\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/news\\\/bristol-myers-squibb-co%ef%bc%9amezigdomide-formally-included-in-the-priority-review-and-approval-procedure\\\/\",\"name\":\"Bristol-Myers Squibb Co\uff1aMezigdomide\u00a0formally included in the priority review and approval procedure. - Xpharma China\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/news\\\/bristol-myers-squibb-co%ef%bc%9amezigdomide-formally-included-in-the-priority-review-and-approval-procedure\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/news\\\/bristol-myers-squibb-co%ef%bc%9amezigdomide-formally-included-in-the-priority-review-and-approval-procedure\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/xpharma.com.cn\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/CgoaEGY7RqmEcEocAAAAAIHLW7c093.png\",\"datePublished\":\"2026-06-04T15:18:48+00:00\",\"dateModified\":\"2026-06-04T15:47:04+00:00\",\"description\":\"Bristol-Myers Squibb Co\uff1aMezigdomide\u00a0formally included in the priority review and approval procedure. - Xpharma China\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/news\\\/bristol-myers-squibb-co%ef%bc%9amezigdomide-formally-included-in-the-priority-review-and-approval-procedure\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/news\\\/bristol-myers-squibb-co%ef%bc%9amezigdomide-formally-included-in-the-priority-review-and-approval-procedure\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/news\\\/bristol-myers-squibb-co%ef%bc%9amezigdomide-formally-included-in-the-priority-review-and-approval-procedure\\\/#primaryimage\",\"url\":\"https:\\\/\\\/xpharma.com.cn\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/CgoaEGY7RqmEcEocAAAAAIHLW7c093.png\",\"contentUrl\":\"https:\\\/\\\/xpharma.com.cn\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/CgoaEGY7RqmEcEocAAAAAIHLW7c093.png\",\"width\":640,\"height\":470},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/news\\\/bristol-myers-squibb-co%ef%bc%9amezigdomide-formally-included-in-the-priority-review-and-approval-procedure\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"\u9996\u9875\",\"item\":\"https:\\\/\\\/xpharma.com.cn\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Bristol-Myers Squibb Co\uff1aMezigdomide\u00a0formally included in the priority review and approval procedure.\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/#website\",\"url\":\"https:\\\/\\\/xpharma.com.cn\\\/\",\"name\":\"Xpharma China - International Pharmaceutical wholesaler and retailer\",\"description\":\"Xpharma China\",\"publisher\":{\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/xpharma.com.cn\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/#organization\",\"name\":\"Xpharma China\",\"url\":\"https:\\\/\\\/xpharma.com.cn\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/xpharma.com.cn\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/logo.gif\",\"contentUrl\":\"https:\\\/\\\/xpharma.com.cn\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/logo.gif\",\"width\":679,\"height\":166,\"caption\":\"Xpharma China\"},\"image\":{\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/61590027634719\\\/\",\"https:\\\/\\\/x.com\\\/Xpharma007\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/#\\\/schema\\\/person\\\/c292b26c0a3311036ce0f5ab28a1ea05\",\"name\":\"xpharmanews\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/5441929ebdec5e836942790743ce7c64c33152cf17fba039e0d79b52418f025f?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/5441929ebdec5e836942790743ce7c64c33152cf17fba039e0d79b52418f025f?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/5441929ebdec5e836942790743ce7c64c33152cf17fba039e0d79b52418f025f?s=96&d=mm&r=g\",\"caption\":\"xpharmanews\"},\"url\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/author\\\/xpharmanews\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Bristol-Myers Squibb Co\uff1aMezigdomide\u00a0formally included in the priority review and approval procedure. - Xpharma China","description":"Bristol-Myers Squibb Co\uff1aMezigdomide\u00a0formally included in the priority review and approval procedure. - Xpharma China","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/xpharma.com.cn\/index.php\/news\/bristol-myers-squibb-co\uff1amezigdomide-formally-included-in-the-priority-review-and-approval-procedure\/","og_locale":"en_US","og_type":"article","og_title":"Bristol-Myers Squibb Co\uff1aMezigdomide\u00a0formally included in the priority review and approval procedure. - Xpharma China","og_description":"Bristol-Myers Squibb Co\uff1aMezigdomide\u00a0formally included in the priority review and approval procedure. - Xpharma China","og_url":"https:\/\/xpharma.com.cn\/index.php\/news\/bristol-myers-squibb-co\uff1amezigdomide-formally-included-in-the-priority-review-and-approval-procedure\/","og_site_name":"Xpharma China","article_publisher":"https:\/\/www.facebook.com\/61590027634719\/","article_published_time":"2026-06-04T15:18:48+00:00","article_modified_time":"2026-06-04T15:47:04+00:00","og_image":[{"width":640,"height":470,"url":"https:\/\/xpharma.com.cn\/wp-content\/uploads\/2026\/06\/CgoaEGY7RqmEcEocAAAAAIHLW7c093.png","type":"image\/png"}],"author":"xpharmanews","twitter_card":"summary_large_image","twitter_creator":"@Xpharma007","twitter_site":"@Xpharma007","twitter_misc":{"Written by":"xpharmanews","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"NewsArticle","@id":"https:\/\/xpharma.com.cn\/index.php\/news\/bristol-myers-squibb-co%ef%bc%9amezigdomide-formally-included-in-the-priority-review-and-approval-procedure\/#article","isPartOf":{"@id":"https:\/\/xpharma.com.cn\/index.php\/news\/bristol-myers-squibb-co%ef%bc%9amezigdomide-formally-included-in-the-priority-review-and-approval-procedure\/"},"author":{"name":"xpharmanews","@id":"https:\/\/xpharma.com.cn\/#\/schema\/person\/c292b26c0a3311036ce0f5ab28a1ea05"},"headline":"Bristol-Myers Squibb Co\uff1aMezigdomide\u00a0formally included in the priority review and approval procedure.","datePublished":"2026-06-04T15:18:48+00:00","dateModified":"2026-06-04T15:47:04+00:00","mainEntityOfPage":{"@id":"https:\/\/xpharma.com.cn\/index.php\/news\/bristol-myers-squibb-co%ef%bc%9amezigdomide-formally-included-in-the-priority-review-and-approval-procedure\/"},"wordCount":299,"commentCount":0,"publisher":{"@id":"https:\/\/xpharma.com.cn\/#organization"},"image":{"@id":"https:\/\/xpharma.com.cn\/index.php\/news\/bristol-myers-squibb-co%ef%bc%9amezigdomide-formally-included-in-the-priority-review-and-approval-procedure\/#primaryimage"},"thumbnailUrl":"https:\/\/xpharma.com.cn\/wp-content\/uploads\/2026\/06\/CgoaEGY7RqmEcEocAAAAAIHLW7c093.png","articleSection":["Approved News"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/xpharma.com.cn\/index.php\/news\/bristol-myers-squibb-co%ef%bc%9amezigdomide-formally-included-in-the-priority-review-and-approval-procedure\/#respond"]}]},{"@type":["WebPage","MedicalWebPage"],"@id":"https:\/\/xpharma.com.cn\/index.php\/news\/bristol-myers-squibb-co%ef%bc%9amezigdomide-formally-included-in-the-priority-review-and-approval-procedure\/","url":"https:\/\/xpharma.com.cn\/index.php\/news\/bristol-myers-squibb-co%ef%bc%9amezigdomide-formally-included-in-the-priority-review-and-approval-procedure\/","name":"Bristol-Myers Squibb Co\uff1aMezigdomide\u00a0formally included in the priority review and approval procedure. - Xpharma China","isPartOf":{"@id":"https:\/\/xpharma.com.cn\/#website"},"primaryImageOfPage":{"@id":"https:\/\/xpharma.com.cn\/index.php\/news\/bristol-myers-squibb-co%ef%bc%9amezigdomide-formally-included-in-the-priority-review-and-approval-procedure\/#primaryimage"},"image":{"@id":"https:\/\/xpharma.com.cn\/index.php\/news\/bristol-myers-squibb-co%ef%bc%9amezigdomide-formally-included-in-the-priority-review-and-approval-procedure\/#primaryimage"},"thumbnailUrl":"https:\/\/xpharma.com.cn\/wp-content\/uploads\/2026\/06\/CgoaEGY7RqmEcEocAAAAAIHLW7c093.png","datePublished":"2026-06-04T15:18:48+00:00","dateModified":"2026-06-04T15:47:04+00:00","description":"Bristol-Myers Squibb Co\uff1aMezigdomide\u00a0formally included in the priority review and approval procedure. - Xpharma China","breadcrumb":{"@id":"https:\/\/xpharma.com.cn\/index.php\/news\/bristol-myers-squibb-co%ef%bc%9amezigdomide-formally-included-in-the-priority-review-and-approval-procedure\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/xpharma.com.cn\/index.php\/news\/bristol-myers-squibb-co%ef%bc%9amezigdomide-formally-included-in-the-priority-review-and-approval-procedure\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/xpharma.com.cn\/index.php\/news\/bristol-myers-squibb-co%ef%bc%9amezigdomide-formally-included-in-the-priority-review-and-approval-procedure\/#primaryimage","url":"https:\/\/xpharma.com.cn\/wp-content\/uploads\/2026\/06\/CgoaEGY7RqmEcEocAAAAAIHLW7c093.png","contentUrl":"https:\/\/xpharma.com.cn\/wp-content\/uploads\/2026\/06\/CgoaEGY7RqmEcEocAAAAAIHLW7c093.png","width":640,"height":470},{"@type":"BreadcrumbList","@id":"https:\/\/xpharma.com.cn\/index.php\/news\/bristol-myers-squibb-co%ef%bc%9amezigdomide-formally-included-in-the-priority-review-and-approval-procedure\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"\u9996\u9875","item":"https:\/\/xpharma.com.cn\/"},{"@type":"ListItem","position":2,"name":"Bristol-Myers Squibb Co\uff1aMezigdomide\u00a0formally included in the priority review and approval procedure."}]},{"@type":"WebSite","@id":"https:\/\/xpharma.com.cn\/#website","url":"https:\/\/xpharma.com.cn\/","name":"Xpharma China - International Pharmaceutical wholesaler and retailer","description":"Xpharma China","publisher":{"@id":"https:\/\/xpharma.com.cn\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/xpharma.com.cn\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/xpharma.com.cn\/#organization","name":"Xpharma China","url":"https:\/\/xpharma.com.cn\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/xpharma.com.cn\/#\/schema\/logo\/image\/","url":"https:\/\/xpharma.com.cn\/wp-content\/uploads\/2026\/04\/logo.gif","contentUrl":"https:\/\/xpharma.com.cn\/wp-content\/uploads\/2026\/04\/logo.gif","width":679,"height":166,"caption":"Xpharma China"},"image":{"@id":"https:\/\/xpharma.com.cn\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/61590027634719\/","https:\/\/x.com\/Xpharma007"]},{"@type":"Person","@id":"https:\/\/xpharma.com.cn\/#\/schema\/person\/c292b26c0a3311036ce0f5ab28a1ea05","name":"xpharmanews","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/5441929ebdec5e836942790743ce7c64c33152cf17fba039e0d79b52418f025f?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/5441929ebdec5e836942790743ce7c64c33152cf17fba039e0d79b52418f025f?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/5441929ebdec5e836942790743ce7c64c33152cf17fba039e0d79b52418f025f?s=96&d=mm&r=g","caption":"xpharmanews"},"url":"https:\/\/xpharma.com.cn\/index.php\/author\/xpharmanews\/"}]}},"_links":{"self":[{"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/posts\/3604","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/comments?post=3604"}],"version-history":[{"count":3,"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/posts\/3604\/revisions"}],"predecessor-version":[{"id":3616,"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/posts\/3604\/revisions\/3616"}],"wp:attachment":[{"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/media?parent=3604"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/categories?post=3604"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/tags?post=3604"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}